Medical Treatment: Sensipar & Alendronate
While surgery is the definitive treatment for most parathyroid disorders, certain patients — especially those who are not surgical candidates — may benefit from medical therapy. Two commonly used medications are Sensipar (Cinacalcet) and Alendronate.
What is Sensipar?
Sensipar, also known by its generic name cinacalcet, is a calcimimetic agent. It works by increasing the sensitivity of calcium-sensing receptors on the parathyroid gland, thereby reducing parathyroid hormone (PTH) production and lowering blood calcium levels.
Indications:
- Secondary hyperparathyroidism in chronic kidney disease
- Parathyroid carcinoma with severe hypercalcemia
- Primary hyperparathyroidism in patients not suitable for surgery
Benefits: It offers good control of serum calcium and PTH levels without requiring surgical intervention.
What is Alendronate?
Alendronate is a bisphosphonate medication that helps to prevent bone loss by inhibiting bone resorption. It does not directly lower PTH or calcium levels but plays a key role in improving bone mineral density (BMD).
Indications:
- Osteoporosis due to long-term hyperparathyroidism
- To reduce fracture risk in patients with decreased bone density
Usage: Often prescribed alongside calcium and vitamin D, particularly in postmenopausal women or elderly patients.
Comparison: Sensipar vs Alendronate
| Feature | Sensipar | Alendronate |
|---|---|---|
| Mechanism | Reduces PTH secretion | Prevents bone loss |
| Effect on Calcium | Lowers calcium | Minimal effect |
| Main Use | Hypercalcemia management | Osteoporosis treatment |
When to Choose Medical Therapy
Medical treatment is generally considered when:
- The patient is elderly or unfit for surgery
- Parathyroid carcinoma is present
- Kidney failure prevents a safe operation
- The patient declines surgery
Regular monitoring of calcium, PTH, and bone density is essential when on medical therapy. Always consult an endocrinologist to determine the most appropriate treatment strategy for your condition.